NCT07083427

Brief Summary

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
122mo left

Started Aug 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Aug 2025Jul 2036

First Submitted

Initial submission to the registry

July 17, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 24, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
9.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2035

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2036

Last Updated

July 24, 2025

Status Verified

July 1, 2025

Enrollment Period

9.9 years

First QC Date

July 17, 2025

Last Update Submit

July 23, 2025

Conditions

Infertility, Female

Outcome Measures

Primary Outcomes (1)

  • Number of mature oocytes

    Number of mature oocytes after IVM

    1 week

Study Arms (1)

CAPA-IVM

EXPERIMENTAL

In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

Other: CAPA-IVM

Interventions

CAPA-IVMOTHER

In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

CAPA-IVM

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients aged from 18-50 years old
  • Patients seek fertility preservation services
  • Patients seek oocyte retrieval services

You may not qualify if:

  • Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prince of Wales Hospital

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Infertility, Female

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesInfertility

Central Study Contacts

Pui Wah Jacqueline Chung, MBBS

CONTACT

3505 2745jacquelinechung@cuhk.edu.hk

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 17, 2025

First Posted

July 24, 2025

Study Start

August 1, 2025

Primary Completion (Estimated)

June 30, 2035

Study Completion (Estimated)

July 1, 2036

Last Updated

July 24, 2025

Record last verified: 2025-07

Locations

HK(1)